Similarity | Rank | |
---|---|---|
placebo-controlled | 0.933 | 42426 |
double-blind | 0.926 | 34234 |
multicenter | 0.904 | 69465 |
randomized | 0.898 | 18214 |
randomised | 0.860 | 46929 |
once-daily | 0.829 | 95649 |
monotherapy | 0.827 | 66795 |
case-control | 0.792 | 83586 |
bevacizumab | 0.785 | 94024 |
Randomized | 0.779 | 93743 |
high-dose | 0.778 | 58378 |
placebo | 0.777 | 12334 |
investigational | 0.777 | 62099 |
meta-analysis | 0.772 | 39189 |
tolerability | 0.765 | 68898 |
preclinical | 0.763 | 49806 |
RCTs | 0.762 | 82390 |
ribavirin | 0.759 | 98039 |
dose-response | 0.758 | 97933 |
antiplatelet | 0.756 | 82232 |
prospectively | 0.753 | 71458 |
pharmacokinetic | 0.751 | 73658 |
low-dose | 0.749 | 57276 |
adjunctive | 0.747 | 74163 |
pharmacologic | 0.746 | 72757 |